Brominated Vegetable Oil vs Recombinant Bovine Growth Hormone: which is worse?

What is Brominated Vegetable Oil?

Brominated vegetable oil (BVO) is a food additive created by bonding bromine atoms to vegetable oil (typically soybean oil), creating a denser-than-water compound. When added to citrus-flavored beverages, BVO acts as an emulsifier and weighting agent, keeping citrus flavor oils evenly distributed throughout the drink rather than floating to the surface.

What is Recombinant Bovine Growth Hormone?

Recombinant bovine growth hormone (rBGH), also called recombinant bovine somatotropin (rBST), is a synthetically produced version of the naturally occurring cattle growth hormone, manufactured using genetically engineered E. coli bacteria. Injected into dairy cows, it increases milk production by 10-15%. It was FDA-approved in 1993 under the brand name Posilac (originally Monsanto, later Elanco).

Documented risks

Brominated Vegetable Oil: BVO's health concerns center on bromine accumulation in body fat and tissues. Bromine is a halogen related to iodine, and it competes with iodine in the body, potentially disrupting thyroid function—a critical concern since iodine is essential for thyroid hormone synthesis. The FDA-NIH collaborative research directly triggering the 2024 ban found adverse cardiac and thyroid effects in animal studies. This FDA-NIH work, published around 2022–2023, showed effects at dose levels closer to realistic human exposure than previous studies, removing the basis for BVO's safety determination under the Federal Food, Drug, and Cosmetic Act's 'reasonable certainty of no harm' standard. Historical case reports of human toxicity from excessive BVO consumption document bromoderma (skin lesions), memory loss, nerve damage, tremors, and fatigue in individuals consuming large volumes of BVO-containing beverages daily. Two well-documented US cases from the 1970s and 1980s involved bromism (bromine toxicity) from chronic overconsumption. Bromine bioaccumulates in fatty tissues. Long-term sub-clinical accumulation was a concern even before the FDA ban, particularly for heavy consumers of citrus sodas. The EU, Japan, and other countries banned BVO decades ago, making the US one of the last major markets to revoke approval. The FDA issued a proposed rule in November 2023 and a final rule on July 3, 2024, effective August 2, 2024, with compliance deadline August 2, 2025, after which BVO-containing products may not be manufactured for US sale.

Recombinant Bovine Growth Hormone: The central human health concern is that rBGH treatment significantly elevates insulin-like growth factor 1 (IGF-1) levels in treated cows' milk. IGF-1 is a naturally occurring growth hormone that promotes cell growth and division. Multiple epidemiological studies have associated elevated blood IGF-1 levels with increased cancer risk in humans. A 1998 study in The Lancet (Hankinson et al.) found that women with the highest IGF-1 blood levels had approximately 7 times the breast cancer risk compared to those with the lowest levels. A 2004 meta-analysis in JNCI (the Journal of the National Cancer Institute) confirmed significant associations between high IGF-1 levels and breast, prostate, and colorectal cancer risk. The mechanistic question is whether consuming rBGH-treated milk raises blood IGF-1 levels in humans. The FDA and WHO/FAO Codex Alimentarius concluded that IGF-1 in milk is a protein largely digested in the GI tract before absorption. Canadian regulatory researchers challenged this, arguing that pasteurization reduces proteases that would otherwise break down IGF-1, potentially allowing more intact IGF-1 to survive digestion. The Codex Alimentarius Commission made history in 1999 by declining to endorse rBST safety maximum residue limits — a split vote (33 in favor of the MRL, 29 against, with abstentions) demonstrating fundamental international disagreement. This is one of very few cases where Codex failed to establish a safety standard. Animal welfare is a second major concern: Health Canada's comprehensive 1999 review found that rBGH-treated cows had 25% higher rates of clinical mastitis, 50% higher lameness risk, increased reproductive problems, and shortened productive lifespans, requiring substantially more antibiotic treatment — an antibiotic resistance concern. Canada rejected rBGH approval in 1999 after its scientific review; the EU banned it in 1999.